Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Consistent improvement with eculizumab across muscle groups in myasthenia gravis / Mantegazza R.; O'Brien F.L.; Yountz M.; Howard J.F.; Gabriel Mazia C.; Wilken M.; Barroso F.; Saba J.; Rugiero M.; Bettini M.; Chaves M.; Vidal G.; Dalila Garcia A.; De Bleecker J.; Van den Abeele G.; de Koning K.; De Mey K.; Mercelis R.; Mahieu D.; Wagemaekers L.; Van Damme P.; Depreitere A.; Schotte C.; Smetcoren C.; Stevens O.; Van Daele S.; Vandenbussche N.; Vanhee A.; Verjans S.; Vynckier J.; D'Hont A.; Tilkin P.; Alves de Siqueira Carvalho A.; Dias Brockhausen I.; Feder D.; Ambrosio D.; Cesar P.; Paula Melo A.; Martins Ribeiro R.; Rocha R.; Bezerra Rosa B.; Veiga T.; Augusto da Silva L.; Santos Engel M.; Goncalves Geraldo J.; da Penha Ananias Morita M.; Nogueira Coelho E.; Paiva G.; Pozo M.; Prando N.; Torres D.D.M.; Fernanda Butinhao C.; Duran G.; Augusto Suriane Fialho T.; Gomes da Silva T.C.; Goncalves L.O.M.; Eduardo Pazetto L.; Renata Cubas Volpe L.; Souza Duca L.; Friedrich M.A.G.; Guerreiro A.; Mohr H.; Pereira Martins M.; da Cruz Pacheco D.; Ferreira L.; Paula Macagnan A.; Pinto G.; de Cassia Santos A.; Souza Bulle Oliveira A.; Amaral de Andrade A.C.; Annes M.; Duarte Silva L.; Cavalcante Lino V.; Pinto W.; Assis N.; Carrara F.; Miranda C.; Souza I.; Fernandes P.; Siddiqi Z.; Phan C.; Narayan J.; Blackmore D.; Mallon A.; Roderus R.; Watt E.; Vohanka S.; Bednarik J.; Chmelikova M.; Cierny M.; Toncrova S.; Junkerova J.; Kurkova B.; Reguliova K.; Zapletalova O.; Pitha J.; Novakova I.; Tyblova M.; Jurajdova I.; Wolfova M.; Andersen H.; Harbo T.; Vinge L.; Krogh S.; Mogensen A.; Vissing J.; Hojgaard J.; Witting N.; Mette Ostergaard Autzen A.; Pedersen J.; Eralinna J.-P.; Laaksonen M.; Oksaranta O.; Harrison T.; Eriksson J.; Rozsa C.; Horvath M.; Lovas G.; Matolcsi J.; Szabo G.; Jakab G.; Szabadosne B.; Vecsei L.; Dezsi L.; Varga E.; Konyane M.; Antonini G.; Di Pasquale A.; Garibaldi M.; Morino S.; Troili F.; Fionda L.; Pasquale A.; Evoli A.; Emilio Alboini P.; D'Amato V.; Iorio R.; Inghilleri M.; Frasca V.; Giacomelli E.; Gori M.; Lopergolo D.; Onesti E.; Gabriele M.; Sacca F.; Filla A.; Costabile T.; Marano E.; Fasanaro A.; Marsili A.; Puorro G.; Antozzi C.; Bonanno S.; Camera G.; Locatelli A.; Maggi L.; Pasanisi M.; Campanella A.; Uzawa A.; Kanai T.; Kawaguchi N.; Mori M.; Kaneko Y.; Kanzaki A.; Kobayashi E.; Murai H.; Masaki K.; Matsuse D.; Matsushita T.; Uehara T.; Shimpo M.; Jingu M.; Kikutake K.; Nakamura Y.; Sano Y.; Utsugisawa K.; Nagane Y.; Kamegamori I.; Tsuda T.; Fujii Y.; Futono K.; Ozawa Y.; Mizugami A.; Saito Y.; Samukawa M.; Suzuki H.; Morikawa M.; Kamakura S.; Miyawaki E.; Okumura M.; Funaka S.; Kawamura T.; Nakamori M.; Takahashi M.; Taichi N.; Hasuike T.; Higuchi E.; Kobayashi H.; Osakada K.; Shiraishi H.; Miyazaki T.; Motomura M.; Mukaino A.; Yoshimura S.; Asada S.; Yoshida S.; Amamoto S.; Kobashikawa T.; Koga M.; Maeda Y.; Takada K.; Takada M.; Tsurumaru M.; Yamashita Y.; Suzuki Y.; Akiyama T.; Narikawa K.; Tano O.; Tsukita K.; Kurihara R.; Meguro F.; Fukuda Y.; Sato M.; Imai T.; Tsuda E.; Shimohama S.; Hayashi T.; Hisahara S.; Kawamata J.; Murahara T.; Saitoh M.; Suzuki S.; Yamamoto D.; Ishiyama Y.; Ishiyama N.; Noshiro M.; Takeyama R.; Uwasa K.; Yasuda I.; van der Kooi A.; de Visser M.; Gibson T.; Kim B.-J.; Nyoung Lee C.; Seo Koo Y.; Youl Seok H.; Nam Kang H.; Ra H.; Joon Kim B.; Bin Cho E.; Choi M.; Lee H.; Min J.-H.; Seok J.; Lee J.; Koh D.Y.; Kwon J.; Park S.; Haw Choi E.; Hong Y.-H.; Ahn S.-H.; Lim Koo D.; Lim J.-S.; Won Shin C.; Ye Hwang J.; Kim M.; Min Kim S.; Jeong H.-N.; Jung J.; Kim Y.-H.; Seok Lee H.; Young Shin H.; Bi Hwang E.; Shin M.; Casasnovas C.; Antonia Alberti Aguilo M.; Homedes-Pedret C.; Julia Palacios N.; Diez Porras L.; Velez Santamaria V.; Lazaro A.; Gamez Carbonell J.; Sune P.; Salvado Figueras M.; Gili G.; Mazuela G.; Illa I.; Cortes Vicente E.; Diaz-Manera J.; Antonio Querol Gutierrez L.; Rojas Garcia R.; Vidal N.; Arribas-Ibar E.; Diez Tejedor E.; Gomez Salcedo P.; Fernandez-Fournier M.; Lopez Ruiz P.; Rodriguez de Rivera F.J.; Sastre M.; Piehl F.; Hietala A.; Bjarbo L.; Sengun I.; Meherremova A.; Ozcelik P.; Balkan B.; Tuga C.; Ugur M.; Erdem-Ozdamar S.; Bekircan-Kurt C.; Pinar Acar N.; Yilmaz E.; Caliskan Y.; Orsel G.; Efendi H.; Aydinlik S.; Cavus H.; Kutlu A.; Becerikli G.; Semiz C.; Tun O.; Terzi M.; Dogan B.; Kazim Onar M.; Sen S.; Kirbas Cavdar T.; Veske A.; Norwood F.; Dimitriou A.; Gollogly J.; Mahdi-Rogers M.; Seddigh A.; Sokratous G.; Maier G.; Sohail F.; Jacob S.; Sadalage G.; Torane P.; Brown C.; Shah A.; Sathasivam S.; Arndt H.; Davies D.; Watling D.; Amato A.; Cochrane T.; Salajegheh M.; Roe K.; Amato K.; Toska S.; Wolfe G.; Silvestri N.; Patrick K.; Zakalik K.; Katz J.; Miller R.; Engel M.; Forshew D.; Bravver E.; Brooks B.; Sanjak M.; Plevka S.; Burdette M.; Cunningham S.; Kramer M.; Nemeth J.; Schommer C.; Scott T.; Juel V.; Guptill J.; Hobson-Webb L.; Massey J.; Beck K.; Carnes D.; Loor J.; Anderson A.; Pascuzzi R.; Bodkin C.; Kincaid J.; Snook R.; Guingrich S.; Micheels A.; Chaudhry V.; Corse A.; Mosmiller B.; Kelley A.; Ho D.; Srinivasan J.; Vytopil M.; Jara J.; Ventura N.; Carter C.; Donahue C.; Herbert C.; Scala S.; Weiner E.; Alam S.; McKinnon J.; Haar L.; McKinnon N.; Alcon K.; McKenna K.; Sattar N.; Daniels K.; Jeffery D.; Freimer M.; Chad Hoyle J.; Kissel J.; Agriesti J.; Chelnick S.; Mezache L.; Pineda C.; Muharrem F.; Karam C.; Khoury J.; Marburger T.; Kaur H.; Dimitrova D.; Gilchrist J.; Agrawal B.; Elsayed M.; Kohlrus S.; Ardoin A.; Darnell T.; Golden L.; Lokaitis B.; Seelbach J.; Muppidi S.; Goyal N.; Sakamuri S.; So Y.T.; Paulose S.; Pol S.; Welsh L.; Bhavaraju-Sanka R.; Tobon Gonzalez A.; Dishman L.; Jones F.; Gonzalez A.; Padilla P.; Saklad A.; Silva M.; Nations S.; Trivedi J.; Hopkins S.; Kazamel M.; Alsharabati M.; Lu L.; Nozaki K.; Mumfrey-Thomas S.; Woodall A.; Mozaffar T.; Cash T.; Goyal N.; Roy G.; Mathew V.; Maqsood F.; Minton B.; James Jones H.; Rosenfeld J.; Garcia R.; Echevarria L.; Garcia S.; Pulley M.; Aranke S.; Ross Berger A.; Shah J.; Shabbir Y.; Smith L.; Varghese M.; Gutmann L.; Gutmann L.; Jerath N.; Nance C.; Swenson A.; Olalde H.; Kressin N.; Sieren J.; Barohn R.; Dimachkie M.; Glenn M.; McVey A.; Pasnoor M.; Statland J.; Wang Y.; Liu T.; Emmons K.; Jenci N.; Locheke J.; Fondaw A.; Johns K.; Rico G.; Walsh M.; Herbelin L.; Hafer-Macko C.; Kwan J.; Zilliox L.; Callison K.; Young V.; DiSanzo B.; Naunton K.; Benatar M.; Bilsker M.; Sharma K.; Cooley A.; Reyes E.; Michon S.-C.; Sheldon D.; Steele J.; Traub R.; Chopra M.; Vu T.; Katzin L.; McClain T.; Harvey B.; Hart A.; Huynh K.; Beydoun S.; Chilingaryan A.; Doan V.; Droker B.; Gong H.; Karimi S.; Lin F.; Polaka K.; Shah A.; Tran A.; Akhter S.; Malekniazi A.; Tandan R.; Hehir M.; Waheed W.; Lucy S.; Weiss M.; Distad J.; Strom S.; Downing S.; Kim B.; Bertorini T.; Arnold T.; Henderson K.; Pillai R.; Liu Y.; Wheeler L.; Hewlett J.; Vanderhook M.; Nowak R.; Dicapua D.; Keung B.; Kumar A.; Patwa H.; Robeson K.; Yang I.; Nye J.; Vu H.. - In: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. - ISSN 2328-9503. - ELETTRONICO. - 7:(2020), pp. 1327-1339. [10.1002/acn3.51121]

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

D'Amato V.
Membro del Collaboration Group
;
2020

Abstract

Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
2020
7
1327
1339
Mantegazza R.; O'Brien F.L.; Yountz M.; Howard J.F.; Gabriel Mazia C.; Wilken M.; Barroso F.; Saba J.; Rugiero M.; Bettini M.; Chaves M.; Vidal G.; Da...espandi
File in questo prodotto:
File Dimensione Formato  
Consistent improvement with eculizumab across muscle groups in myasthenia gravis.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 521.31 kB
Formato Adobe PDF
521.31 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1258327
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact